Search PubMed⌕ Search

SEARCH · Search PubMed

Results for “Tranexamic Acid”

Search indexed PubMed citations on genomics, clinical trials, systematic reviews and public health. Explore titles, authors and supplied subject terms, then open the PubMed record.

Quote a phrase for an exact phrase match. Source license links do not imply unrestricted reuse.

At least 1,441 records · Page 80Linked to original sources

[Blind spots of the diagnostic hemostasis screen].

The most powerful instrument to establish the presence or absence of a coagulation disorder is the history of the patient. In addition, screening laboratory tests (consisting of the platelet count, bleeding time and global clotting assays, such as the prothrombin time and the activated partial thromboplastin time) may be helpful to support the diagnosis. In two patients, a 21-year-old man and a 10-year-old girl, with a marked history of enhanced bleeding normal screening laboratory tests were found. The male patient had a congenital alpha 2-antiplasmin deficiency and the girl had a homozygous deficiency of factor XIII. Some defects in the coagulation system (such as defects in fibrin network formation and fibrinolysis, but also mild Von Willebrand disease) are indeed not detected by screening laboratory tests. In patients with a strong suspicion of a coagulation disorder such defects should be specifically tested for.

Adult↗

Alternatives to hysterectomy for the treatment of excessive uterine bleeding.

Abnormal uterine bleeding is a common gynaecological problem that traditionally has been treated with hysterectomy. However, there are many other conservative treatment modalities that should be considered before hysterectomy. Medical therapies are effective in most cases. Endometrial ablation may be an effective surgical alternative to hysterectomy. This article reviews and updates the diagnostic concepts and management options for the treatment of abnormal uterine bleeding. The authors present a review of the pertinent literature and describe their experience with the latest balloon device for endometrial ablation therapy.

Anti-Inflammatory Agents, Non-Steroidal↗

Relationship between factor VII activity and clinical efficacy of recombinant factor VIIa given by continuous infusion to patients with factor VIII inhibitors.

A multicenter prospective study of recombinant activated factor VII (rFVIIa) given by continuous infusion (CI) to treat severe hemorrhages and to handle surgical procedures was carried out. Relations between clinical efficacy, dosages used and levels of FVII coagulant activity (FVII:C) achieved in plasma were also evaluated. Case material included 25 patients with hemophilia (9 children and 16 adults) with high-responding inhibitors and 3 patients with acquired factor VIII inhibitors. Overall, 35 CI courses were given for 10 spontaneous bleeding episodes, 11 major surgical procedures and 14 minor surgical procedures. Bolus doses of 90 to 150 microg/kg (median: 100) were followed by CI given at median rates of 20 microg/kg/h for major surgery and of 17 and 16 microg/kg/h for minor surgery and spontaneous hemorrhages. Satisfactory hemostasis was obtained in 30 of 35 courses (88%). rFVIIa CI was ineffective in 2 hemophiliacs undergoing surgical operations and in another hemophiliac with hemoperitoneum who had to be switched to other treatments (high doses of porcine or human factor VIII concentrates). rFVIIa CI was partially effective in 2 hemophiliacs who had mild local bleeding after minor surgery. The CI rates and the corresponding FVII:C levels in plasma were similar in effective, partially effective and ineffective courses (median rate: 17, 20 and 20 microg/kg/h, respectively; median FVII:C:14, 18 and 18 IU/ml, respectively). A single adverse event was observed, superficial thrombophlebitis. This study confirms that rFVIIa given by CI is effective in a high proportion of patients with factor VIII inhibitors. It also demonstrates that FVII:C levels attained in plasma do not always predict efficacy because similarly high levels were attained during successful treatments and in those that failed.

Adult↗

Possible role of plasminogen activator in the occurrence of profuse watery rhinorrhea after topical application of epinephrine to the nasal mucosa.

Epinephrine and lidocaine have been used for the diagnosis and treatment of nasal diseases. However, watery rhinorrhea and frequent sneezing occur in many patients after topical application of these drugs to the nasal mucosa. This study was aimed at characterizing these side effects, and developing a means to prevent such side effects. A questionnaire was given to each patient who complained of side effects after treatment with epinephrine and lidocaine, and the answers were analyzed with respect to the occurrence and features of the symptoms after the treatment. Eosinophil and mast cell numbers were determined in nasal smears from the patients with side effects. These side effects were different from rhinitis medicamentosa and allergic rhinitis, and were due to epinephrine, not to lidocaine or to the preservatives in the epinephrine. Tranexamic acd, an inhibitor of plasmin, was effective in blocking the side effects.

Administration, Topical↗

Menorrhagia.

Explore the source record for details and available documents.

Anti-Inflammatory Agents, Non-Steroidal↗

[Clinical study on rebleeding of cerebral anuerysms--with special references to the warning signs of rebleeding and antifibrinolytic treatment during waiting time for surgery (author's transl)].

The warning signs of rebleeding in the ruptured cerebral aneurysms, and the effect of antifibrinolytic treatment on the prevention of rebleeding from the ruptured aneurysms were studied and evaluated satistically by analysing the 62 single ruptured aneurysms. The incidennce of rebleeding during waiting time for surgery was higher in the following factors, i.e., the older patients, the Grade 2, the higher blood pressure, the larger aneurysms, the anterior-communicating aneurysms, the vasospasm. The critical time for rerupture was within three days after admission and within seven days after last bleeding. The anti-edema treatment and the sedation treatment have no effect upon the rebleeding. There was no difference in incidence of rebleeding among the sex and the frequency of bleeding before admission. The operative mortality of the reruptured patients during waiting time for surgery was very high. The antifibrinolytic treatment definitely lessened the incidence of rebleeding of the ruptured aneurysms during waiting time for surgery, and there were no noticeable complications following this treatment. This treatment is of value in the prevention of rebleeding from ruptured cerebral aneurysms during waiting time for surgery.

Adult↗

Decreasing bleeding effect of transamin on the induced abortion.

OBJECTIVE: To confirm the decreasing bleeding effect of transamin on the induced abortion for the early pregnancy with more than two months. METHODS: A total of 120 women are divided into two groups (60 pairs) based on the pelvic examination and the size of embryo measured by B ultrasound. Those women in the treated group (n = 60) were administed Transamin 1 g/20 ml (iv for 5 minutes) 30 minutes before operation; control group (n = 60) were given 5% glucose and saline 20 ml (iv for 5 minutes) 30 minutes before operation. RESULTS: There wasn't any singnificant difference (P > 0.05) between the two groups in the patient's age, pregnancy age, parities, the cavity volume of uterine, hemoglobin and blood platelet count. The bleeding volume was (51.6 +/- 17.2) ml for the treated group and (63.3 +/- 17.1) ml for the control group (P < 0.05). CONCLUSIONS: Transamin has effective hemostasis during the induced abortion for the early pregnancy with > 2 months. It could decrease the volume of bleeding during the operation and benefit for patients recovering.

Abortion, Induced↗

Menorrhagia.

Explore the source record for details and available documents.

Anti-Inflammatory Agents, Non-Steroidal↗

Treatment of anaemia in the polytrauma Jehovah's Witness.

The management of Jehovah's Witnesses can prove quite challenging to the surgeon who routinely uses blood and blood products in the treatment of anaemia and hypovolaemia. The medical and legal dilemmas are exacerbated when the patient has a critically low haemoglobin level or has suffered life-threatening blood loss following polytrauma. It is essential that the treating physician should have some knowledge and understanding of the beliefs of the Jehovah's Witness in order to effectively minimise and treat blood loss. This paper reviews the ethical and medicolegal aspects involved, as well as alternatives to allogenic blood products in the treatment of anaemia in the polytrauma Jehovah's Witness patient.

Anemia↗